Alternative schedule ipilimumab plus nivolumab for first-line treatment of advanced kidney cancer

The combination of nivolumab with ipilimumab has been proven to be effective in the treatment of patients with metastatic renal cell carcinoma (RCC), and is available as a first line treatment via the Cancer Drugs Fund in England and Wales. In the current UK-based study (PRISM), which is still ongoing, researchers are assessing whether less frequent dosing of ipilimumab (every 12 weeks versus every 3 weeks), in combination with nivolumab, is better tolerated and still as effective as the more frequent dosing schedule.

The results so far suggest that the quality of life of patients might be improved with the less frequent dosing schedule for ipilimimab, and patients are experiencing less toxicity without compromising efficacy.

Read more in BMC Cancer here

Share this Post!


Related post

  TOP